REGN7508用于成年参与者预防癌症相关血栓形成 (ROXI-CAT-I)
一项评估REGN7508(一种抗FXI单克隆抗体)用于接受癌症治疗的实体瘤参与者癌症相关血栓形成一级预防的有效性和安全性的3期、多中心、随机、双盲、安慰剂对照研究(ROXI-CAT-I)
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Clinical Trials Administrator
- 电话号码:844-734-6643
- 邮箱:clinicaltrials@regeneron.com
学习地点
-
-
-
Tbilisi、乔治亚州、0159
- 招聘中
- Institute of Clinical Oncology
-
Tbilisi、乔治亚州、0186
- 招聘中
- Caucasus Medical Centre
-
Tbilisi、乔治亚州、0144
- 招聘中
- Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
-
Tbilisi、乔治亚州、0179
- 招聘中
- LTD Cancer Research Centre
-
Tbilisi、乔治亚州、0179
- 招聘中
- JSC Evex Hospitals - Caraps Medline
-
Tbilisi、乔治亚州、0102
- 招聘中
- American Hospital Tbilisi
-
Tbilisi、乔治亚州、0112
- 招聘中
- Llc Todua Clinic
-
Tbilisi、乔治亚州、0112
- 招聘中
- Israel Georgia Medical Research Clinic Helsicore
-
-
Adjara
-
Batumi、Adjara、乔治亚州、6000
- 招聘中
- LTD High Technology Hospital Medcenter
-
-
Imereti
-
Kutaisi、Imereti、乔治亚州、4600
- 招聘中
- Krystyna Kiel Oncology Center
-
-
-
-
-
Niigata、日本、951-8520
- 招聘中
- Niigata University Medical & Dental Hospital
-
-
Ehime
-
Tōon、Ehime、日本、791-0295
- 招聘中
- Ehime University Hospital
-
-
Gunma
-
Ōta、Gunma、日本、373-8550
- 招聘中
- Gunma Prefectural Cancer Center
-
-
Hyōgo
-
Akashi、Hyōgo、日本、673-8558
- 招聘中
- Hyogo Cancer Center
-
-
Kagawa-ken
-
Kita-gun、Kagawa-ken、日本、761-0793
- 招聘中
- Kagawa University Hospital
-
-
Kanagawa
-
Isehara-Shi、Kanagawa、日本、259-1193
- 招聘中
- Tokai University Hospital
-
-
Kyoto
-
Kyoto、Kyoto、日本、602-8566
- 招聘中
- University Hospital Kyoto Prefectural University of Medicine
-
-
Miyagi
-
Sendai、Miyagi、日本、980-8574
- 招聘中
- Tohoku University Hospital
-
-
Osaka
-
Chuo、Osaka、日本、540-0006
- 招聘中
- National Hospital Organization Osaka National Hospital (ONH)
-
-
Saitama
-
Ina-machi、Saitama、日本、362-0806
- 招聘中
- Saitama Cancer Center
-
-
Tokyo
-
Chuo Ku、Tokyo、日本、104-0045
- 招聘中
- National Cancer Center Hospital - Tsukiji Campus
-
Shinjuku、Tokyo、日本、160-0023
- 招聘中
- Tokyo Medical University Hospital
-
-
Yamaguchi
-
Ube、Yamaguchi、日本、755-8505
- 招聘中
- Yamaguchi University Hospital
-
-
-
-
Florida
-
Hialeah、Florida、美国、33013
- 招聘中
- Bioresearch Partner- Hialeah Hospital
-
North Miami Beach、Florida、美国、33169
- 招聘中
- Helios Clinical Research
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- 招聘中
- Beth Israel Deaconess Medical Center
-
-
New York
-
New York、New York、美国、10021
- 招聘中
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
El Paso、Texas、美国、79902
- 撤销
- El Paso Medical Research Institute (Medresearch Inc)
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol
- Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with a similar increased risk of VTE as described in the protocol
- Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention
Key Exclusion Criteria:
- Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)
- Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma
- Has a primary brain tumor or brain metastases as described in the protocol
- Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period
- Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm if he/she participated in the study
Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:安慰剂
|
Administered per the protocol |
|
实验性的:雷根7508
|
Administered per the protocol
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
经中心判定的国际血栓与止血学会(ISTH)大出血或临床相关非大出血(CRNM)首次事件发生时间
大体时间:通过6个月
|
通过6个月
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death
大体时间:Through 6 months
|
Through 6 months
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
治疗期间出现的不良事件(TEAE)发生率
大体时间:截至第 245 天
|
截至第 245 天
|
|
不良事件严重程度
大体时间:截至第245天
|
截至第245天
|
|
REGN7508抗体药物抗体的滴度
大体时间:截至第 245 天
|
截至第 245 天
|
|
Time-to-first event of the centrally adjudicated symptomatic or incidental VTE (DVT, PE) or ATE and thromboembolism- or ATE-related death
大体时间:Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic VTE
大体时间:Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic DVT
大体时间:Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic non-fatal PE
大体时间:Through 6 months
|
Through 6 months
|
|
Time-to-first event of thromboembolism-related death
大体时间:Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental VTE
大体时间:Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental upper extremity or incidental proximal lower extremity DVT
大体时间:Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental non-fatal PE (in a segmental or larger pulmonary artery)
大体时间:Through 6 months
|
Through 6 months
|
|
Time-to-first event of asymptomatic VTE (Asymptomatic DVT detected by lower extremities ultrasound)
大体时间:Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE
大体时间:Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE-related death
大体时间:Through 6 months
|
Through 6 months
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE), or thromboembolism-related death
大体时间:Through 6 months
|
Through 6 months
|
|
Occurrence of Anti-Drug Antibody (ADA) to REGN7508
大体时间:Up to day 245
|
Up to day 245
|
合作者和调查者
调查人员
- 研究主任:Clinical Trial Management、Regeneron Pharmaceuticals
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- R7508-CAT-2392
- 2024-519298-21-00 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD 共享时间框架
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 共享访问标准
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.